Key Takeaways
- Margin delivery ahead of plan: Consolidated EBITDA margin reached 18.94% for FY25, exceeding the ~18% guidance, while Unichem hit its margin target a full year early.
- Domestic formulation is the engine: Domestic business grew 13.2% for the full year, outpacing the market by over 500 bps, with chronic segment growth nearly double the market rate.
- API business is stabilizing: After a prolonged post-COVID price decline, management sees stability emerging and expects both volume and price growth in FY26.
- Unichem synergies are still a future story: Not a single Ipca API is qualified at Unichem yet, and no Unichem product has been approved in other markets; all integration benefits lie ahead.
- What to watch next quarter: Whether the four greenfield plants begin trial production on schedule, the pace of U.S. product commercialization, and any tariff-related guidance revision.
Domestic Formulation
- Broad-based market share gains: Domestic business delivered 11% Q4 growth and 13.2% full-year growth, outperforming the overall market growth of ~8%. Both acute (10.9% vs market 6.9%) and chronic (17.9% vs market 9.8%) segments grew faster than the market.
- Chronic mix is understated: Ipca's chronic contribution is 34% versus the market's 39%, but rheumatoid arthritis therapies, which involve lifelong disease-modifying agents, are not classified as chronic by the market. Including them would lift Ipca's chronic share.
- Metro coverage drove share: Post-COVID expansion into metro cities helped lift Ipca's market share in the top 30 cities from 32.65% to 37.52%, a gain of nearly 467 bps, while those cities' contribution to the overall market rose from 32.66% to 34.19%.
- Per-man productivity rising: With the business growing ~12% and 400 to 500 people added annually, per-man productivity also increased by 12%. Management expects productivity to compound at ~8% over the next 3 to 4 years.
Harish Kamath: "Next 3 to 4 years, we will beat the market growth, and we should grow 1.5x market growth."
Margin Progression
- Stand-alone margin jump: Stand-alone Q4 EBITDA margin improved 266 bps YoY to 21.19%, and the full-year margin improved 337 bps to 22.66%.
- Consolidated margin beat: Consolidated Q4 EBITDA margin improved 326 bps to 18.24%, and the full-year margin improved 222 bps to 18.94%, exceeding the ~18% guidance given for the year.
- Unichem margin turnaround: Unichem EBITDA improved from INR87 crores to INR265 crores, with the last two quarters in the 14% to 16% range. The acquisition's margin guidance was achieved one year ahead of schedule.
- Unichem Q4 gross margin dip was mix-driven: The sharp decline from 64% to 55% was due to product mix changes, including a rise in contract manufacturing from INR58 crores to INR90 crores, where material cost is higher but marketing costs are absent. Nothing one-off.
- Unichem margin ceiling: Management sees 18% to 20% as the maximum achievable margin for Unichem because it operates only in generics and API, with no branded premium.
Harish Kamath: "See, ideally, our intention, the margin should grow to around 18%, 18% to 20%. That is the maximum what we can achieve because they are into only generic business, and API business."
Export Formulation
- Branded exports slowed in Q4: Branded formulation business grew ~10% for the full year but only ~3% in Q4.
- Generic exports recovered in Q4: Generic business grew ~15% in Q4, lifting full-year growth to ~7%. The full-year figure was dragged down by a 74% decline in South Africa (from INR113 crores to INR39 crores) due to tender losses.
- CIS growth muted by currency: CIS branded business grew only 2% in value terms despite volume growth, because the dollar-ruble rate crossed INR90 before settling at INR79. Management guides ~10% growth from CIS in FY26.
- Regional bright spots: West Africa grew 34%, Southeast Asia 24%, Latin America 17%. Europe grew 10%. Institutional business grew 33% to INR355 crores, partly because the injectable line was undergoing modernization in FY24, depressing the base.
- U.S. is still nascent: The U.S. contributed only ~INR65 crores in FY25. Management expects ~INR100 crores in FY26, with 5 to 6 products commercialized and 6 to 7 new filings planned, most backed by Ipca's own APIs.
Ajit Kumar: "As far as Ipca is concerned, U.S. has not made any significant overall contribution to the overall generic business."
API Business
- Pricing pressure is easing: API pricing peaked during COVID and has been on a consistent downward trend since. Volume improved but value did not reflect it. Management now sees stability emerging and expects prices to start improving slightly from current levels.
- FY26 outlook turns positive: For the first time in the cycle, management expects both volume growth and price growth in the API business in FY26. Some market pickup was already visible in Q4.
Harish Kamath: "But now there is a stability slowly, we feel it will start slightly improving from this level. So in the current financial year... FY '26, you will see volume growth as well as price growth when it comes to the API business."
Unichem Integration
- Synergies are entirely unrealized: Not a single Ipca API has been qualified in Unichem yet, and not a single Unichem product has been approved in other markets. All cross-market selling, API qualification, and product approval benefits are still work in progress.
- Filings have begun, approvals will take time: Unichem's filings have started but management is not including any synergy benefits in guidance until approvals actually come through.
- Capacity is ready, no fresh investment needed: Unichem has significant available capacity to grow, so no new facility investment is required in the immediate future. Its major Goa formulation facility commenced commercial production only last year.
- FY26 expectations: Unichem is guided to deliver 8% to 10% top-line growth and ~100 bps of EBITDA margin improvement in FY26, with revenue growth of 10% to 12% over the next 2 to 3 years.
Manufacturing Expansion
- Four greenfield plants entering trial production in FY26: A monoclonal antibody facility at Pithampur (Madhya Pradesh), an intermediate API facility at Wardha (near Nagpur), a domestic formulation facility at Dewas, and a Pisgah facility in North Carolina for injectables and oral liquids.
- Scale-up is a FY27-28 story: Trial production begins in FY26, but meaningful scale-up from these plants will only be visible from FY27 and FY28 onwards. The Pithampur API facility specifically will scale up only in FY27.
- U.S. pipeline building: 5 to 6 products will be commercialized in the U.S. in FY26, with a pipeline for new product commercialization year after year. Product development for the U.S. market has been ramped up, with capacity to develop ~20 products globally per year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | 8% to 10% growth | FY26 |
| Consolidated EBITDA margin | Improve ~100 bps to ~20% | FY26 |
| Unichem revenue growth | 8% to 10% growth | FY26 |
| Unichem EBITDA margin | Improve ~100 bps | FY26 |
| Unichem medium-term revenue growth | 10% to 12% CAGR | Next 2-3 years |
| Unichem medium-term margin ceiling | 18% to 20% | Medium term |
| U.S. business contribution | ~INR100 crores | FY26 |
| U.S. product shipments | ~7 more products shipped | FY26 |
| U.S. filings | 6 to 7 products filed | FY26 |
| R&D spend | ~4% of stand-alone revenue (including biotech) | FY26 |
| CIS branded growth | ~10% growth | FY26 |
| Export formulation growth | 10% to 11% growth | FY26 |
| API business | Volume growth and price growth | FY26 |
| Domestic business growth vs market | 1.5x market growth | Next 3-4 years |
| New plant trial production | Four greenfield plants begin trials | FY26 |
| New plant scale-up | Meaningful revenue contribution begins | FY27-FY28 |
| U.S. business medium-term potential | INR300-400 crores (per an analyst's math, described as possible by management) | 3-4 years |
| Tariff risk | Guidance given without considering tariffs; variation expected if tariffs are imposed | Conditional |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Standalone revenue growth | ~12% overall business growth |
| Domestic formulation revenue growth | ~11% YoY for Q4; ~13.2% for full year per IQVIA |
| Standalone EBITDA margin | 21.19%, up from 18.5% in Q4 FY24, an improvement of ~2.66 ppt |
| Standalone EBITDA | ₹347 cr, up from ₹279 cr in Q4 FY24, an increase of ~24% |
| Consolidated EBITDA margin | 18.24%, up from 14.98% in Q4 FY24, an improvement of ~3.26 ppt |
| Consolidated EBITDA | ₹410 cr, up from ₹305 cr in Q4 FY24, an increase of ~35% |
| Consolidated revenue growth guidance (FY26) | 8% to 10% |
| Consolidated EBITDA margin guidance (FY26) | ~20%, up from 18.94% in FY25, an improvement of ~1 ppt |
| Domestic acute segment growth | ~10.9% vs market growth of 6.9% per IQVIA |
| Domestic chronic segment growth | ~17.9% vs market growth of ~9.8% per IQVIA |
| Branded formulation export growth | ~3% YoY for Q4; ~10% for full year |
| Generic formulation export growth | ~15% YoY for Q4, from ₹312 cr to ~₹357 cr |
| API business growth | 2% YoY for Q4; 1% for full year |
| Unichem revenue | ~₹2,211 cr for full year, growth of ~18% |
| Unichem EBITDA | ~₹265 cr for full year, up from ₹87 cr |
| U.S. revenue (Ipca standalone shipments) | ₹65 cr shipped; ~₹22-23 cr recognized on consolidated basis |
| U.S. revenue (Unichem) | ₹1,317 cr for full year, growth of ~22% vs ₹1,077 cr in FY24 |
| R&D expenditure (standalone) | ~3.25% of revenue; expected to be ~4% in FY26 including biotech |
| South Africa generic business | ~₹39 cr for full year, decline of ~74% from ₹113 cr due to tender losses |
| Institutional business | ~₹355 cr for full year, growth of ~33% from ₹267 cr |
| MR addition (FY26) | ~400 planned |
| Capex (FY25 actual) | ~₹600 cr spent; FY25 plus FY26 combined ~₹1,000 cr |